EuroPCR 2023 | Left Main Coronary Artery Angioplasty: One or Two Stents?

The EBC MAIN LM study randomized 467 patients with severe left main coronary artery (LCA) lesions to receive provisional stenting or a two-sent strategy (Resolute or Onix stent). The two-stent strategy was decided by the operator (culotte, DK-minicrush, T/TAP).

The crossover rate from those randomized to provisional stenting was 22%.

After a 3-year follow-up, the composite of death, acute myocardial infarction (AMI), and treated lesion revascularization (TLR) was similar (23% vs. 29%; p = 0.13).

Mortality and AMI rates were similar (10% vs. 13%; p = 0.27, and 12% vs.11%; p = 0.75). TLR rates were lower in patients who received provisional stenting (8% vs. 14%; p = 0.02), and most reinterventions were in the circumflex artery ostium.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Reference: “EBC MAIN in the LM”, presentado por el Dr. David Hildick-Smith en el Congreso EuroPCR 2023, realizado en París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....